Standard Article

Neoplastic Disease Diagnosis, DNA in

Biotechnology

  1. Mukesh Verma,
  2. Jacob Kagan,
  3. Sudhir Srivastava

Published Online: 15 SEP 2006

DOI: 10.1002/3527600906.mcb.200400077

Reviews in Cell Biology and Molecular Medicine

Reviews in Cell Biology and Molecular Medicine

How to Cite

Verma, M., Kagan, J. and Srivastava, S. 2006. Neoplastic Disease Diagnosis, DNA in. Reviews in Cell Biology and Molecular Medicine. .

Author Information

  1. Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA

Publication History

  1. Published Online: 15 SEP 2006

This is not the most recent version of the article. View current version (26 JUL 2016)

Abstract

Cancer development involves several stages: initiation, development, and progression. Biomarkers can be used to detect cancer in different stages. The desirable property and utility of a biomarker lies in its ability to provide an early indication of disease progression. Biomarkers should be easy to detect; measurable across populations; and suitable for detection at an early stage, identification of high-risk individuals, early detection of recurrence, and as an intermediate endpoint in chemoprevention. Recent technological advances have helped develop noninvasive, sensitive, and specific biomarkers in small clinical samples to detect preneoplasia.

Keywords:

  • Biomarkers;
  • Cluster Analysis;
  • DNA Hypermethylation;
  • Early Detection;
  • Epigenetics;
  • Mass Spectrometry;
  • Proteomics;
  • SELDI-TOF ;
  • Sensitivity and Specificity